You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 12, September 22/29, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Neuromuscular diseases
 •Quality of Life
 •Immunology
 •Immunology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intravenous Immunoglobulin and Quality of Life

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The clinical review by Dr Dalakas1 underscores that intravenous immunoglobulin (IVIG) is the treatment of choice in Guillain-Barré syndrome (GBS), multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy (CIDP) and that it is useful instead of plasma exchange for management of myasthenia gravis. On the other hand, he stresses the necessity of further studies of dose-finding effects, pharmacoeconomics, and quality of life (QOL) assessments to improve the evidence base for clinical practice.

We believe that our research is a step in this direction. We prospectively followed up 25 patients treated with IVIG to evaluate the early effects on their health-related QOL.2 The patients (15 male, 10 female; mean age, 51.3 [SD, 16.8] years; range, 17-77), were admitted to our Neurology department: 8 with CIDP, 3 with GBS, 3 with multifocal motor neuropathy, 1 with multineuropathy of cranial nerves, and 10 with myasthenia gravis. All were treated with . . . [Full Text of this Article]

Luca Padua, MD, PhD
lpadua@rm.unicatt.it
Fondazione Pro Iuventute
Istituto Don C. Gnocchi
Rome, Italy

Irene Aprile, MD; Pietro Caliandro, MD; Costanza Pazzaglia, MD; Pietro Tonali, MD
Institute of Neurology
Università Cattolica
Rome



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Intravenous Immunoglobulin and Quality of Life—Reply
Marinos C. Dalakas
JAMA. 2004;292(12):1429-1430.
EXTRACT | FULL TEXT  

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Marinos C. Dalakas
JAMA. 2004;291(19):2367-2375.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.